Skip to main content
NCBI home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2010 Oct 8;26(5):417–427. doi: 10.1007/s12264-010-0515-1

Regulation of β cleavage of amyloid precursor protein

淀粉样前体蛋白β切割的调控

Jun-Feng Wang 1, Rui Lu 1, Yi-Zheng Wang 1,✉
PMCID: PMC5560349  PMID: 20882069

Abstract

Alzheimer’s disease ranks the first cause for senile dementia. The amyloid cascade is proposed to contribute to the pathogenesis of this disease. In this cascade, amyloid β peptide (Aβ) is produced through a sequential cleavage of amyloid precursor protein (APP) by β and γ secretases, while its cleavage by α secretase precludes Aβ production and generates neurotrophic sAPPα. Thus, enhancing αsecretase activity or suppressing βand γcleavage may reduce A βformation and ameliorate the pathological process of the disease. Several regulatory mechanisms of APP cleavage have been established. The present review mainly summarizes the signaling pathways pertinent to the regulation of APP β cleavage.

Keywords: Alzheimer’s disease, amyloid β peptide, amyloid precursor protein, β secretase

References

  • [1].Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3:186–191. doi: 10.1016/j.jalz.2007.04.381. [DOI] [PubMed] [Google Scholar]
  • [2].Selkoe D.J. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140:627–638. doi: 10.7326/0003-4819-140-8-200404200-00047. [DOI] [PubMed] [Google Scholar]
  • [3].Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572–580. doi: 10.1002/ana.410300410. [DOI] [PubMed] [Google Scholar]
  • [4].Selkoe D.J. Alzheimer’s disease is a synaptic failure. Science. 2002;298:789–791. doi: 10.1126/science.1074069. [DOI] [PubMed] [Google Scholar]
  • [5].Mudher A., Lovestone S. Alzheimer’s disease-do tauists and baptists finally shake hands? Trends Neurosci. 2002;25:22–26. doi: 10.1016/S0166-2236(00)02031-2. [DOI] [PubMed] [Google Scholar]
  • [6].Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. doi: 10.1126/science.1072994. [DOI] [PubMed] [Google Scholar]
  • [7].Hardy J. Has the amyloid cascade hypothesis for Alzheimer’s disease been proved? Curr Alzheimer Res. 2006;3:71–73. doi: 10.2174/156720506775697098. [DOI] [PubMed] [Google Scholar]
  • [8].Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature. 2006;440:352–357. doi: 10.1038/nature04533. [DOI] [PubMed] [Google Scholar]
  • [9].Dahlgren K.N., Manelli A.M., Stine W.B., Jr, Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046–32053. doi: 10.1074/jbc.M201750200. [DOI] [PubMed] [Google Scholar]
  • [10].Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087–1093. doi: 10.1016/S0896-6273(03)00787-6. [DOI] [PubMed] [Google Scholar]
  • [11].Ohno M., Cole S.L., Yasvoina M., Zhao J., Citron M., Berry R., et al. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis. 2007;26:134–145. doi: 10.1016/j.nbd.2006.12.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest. 2005;115:1121–1129. doi: 10.1172/JCI25100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Roychaudhuri R., Yang M., Hoshi M.M., Teplow D.B. Amyloid β-protein assembly and Alzheimer disease. J Biol Chem. 2009;284:4749–4753. doi: 10.1074/jbc.R800036200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Thinakaran G., Koo E.H. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615–29619. doi: 10.1074/jbc.R800019200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15].Mills J., Reiner P.B. Regulation of amyloid precursor protein cleavage. J Neurochem. 1999;72:443–460. doi: 10.1046/j.1471-4159.1999.0720443.x. [DOI] [PubMed] [Google Scholar]
  • [16].Lee M.S., Kao S.C., Lemere C.A., Xia W., Tseng H.C., Zhou Y., et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol. 2003;163:83–95. doi: 10.1083/jcb.200301115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Oishi M., Nairn A.C., Czernik A.J., Lim G.S., Isohara T., Gandy S.E., et al. The cytoplasmic domain of Alzheimer’s amyloid precursor protein is phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and cultured cells. Mol Med. 1997;3:111–123. [PMC free article] [PubMed] [Google Scholar]
  • [18].da Cruz e Silva E.F., da Cruz e Silva O.A. Protein phosphorylation and APP metabolism. Neurochem Res. 2003;28:1553–1561. doi: 10.1023/A:1025630627319. [DOI] [PubMed] [Google Scholar]
  • [19].Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., et al. Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron. 2008;59:43–55. doi: 10.1016/j.neuron.2008.06.018. [DOI] [PubMed] [Google Scholar]
  • [20].Suzuki T., Nakaya T. Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. J Biol Chem. 2008;283:29633–29637. doi: 10.1074/jbc.R800003200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Ando K., Iijima K.L., Elliott J.I., Kirino Y., Suzuki T. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of β-amyloid. J Biol Chem. 2001;276:40353–40361. doi: 10.1074/jbc.M106460200. [DOI] [PubMed] [Google Scholar]
  • [22].Sabo S.L., Lanier L.M., Ikin A.F., Khorkova O., Sahasrabudhe S., Greengard P., et al. Regulation of β-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem. 1999;274:7952–7957. doi: 10.1074/jbc.274.12.7952. [DOI] [PubMed] [Google Scholar]
  • [23].Santiard-Baron D., Langui D., Delehedde M., Delatour B., Schombert B., Touchet N., et al. Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in β-amyloid load. J Neurochem. 2005;93:330–338. doi: 10.1111/j.1471-4159.2005.03026.x. [DOI] [PubMed] [Google Scholar]
  • [24].Pietrzik C.U., Yoon I.S., Jaeger S., Busse T., Weggen S., Koo E.H. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci. 2004;24:4259–4265. doi: 10.1523/JNEUROSCI.5451-03.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].Miller C.C., McLoughlin D.M., Lau K.F., Tennant M.E., Rogelj B. The X11 proteins, Abeta production and Alzheimer’s disease. Trends Neurosci. 2006;29:280–285. doi: 10.1016/j.tins.2006.03.001. [DOI] [PubMed] [Google Scholar]
  • [26].Sastre M., Turner R.S., Levy E. X11 interaction with beta-amyloid precursor protein modulates its cellular stabilization and reduces amyloid β-protein secretion. J Biol Chem. 1998;273:22351–22357. doi: 10.1074/jbc.273.35.22351. [DOI] [PubMed] [Google Scholar]
  • [27].Lee J.H., Lau K.F., Perkinton M.S., Standen C.L., Shemilt S.J., Mercken L., et al. The neuronal adaptor protein X11α reduces Aβ levels in the brains of Alzheimer’s APPswe Tg2576 transgenic mice. J Biol Chem. 2003;278:47025–47029. doi: 10.1074/jbc.M300503200. [DOI] [PubMed] [Google Scholar]
  • [28].Lee J.H., Lau K.F., Perkinton M.S., Standen C.L., Rogelj B., Falinska A., et al. The neuronal adaptor protein X11α reduces amyloid β-protein levels and amyloid plaque formation in the brains of transgenic mice. J Biol Chem. 2004;279:49099–49104. doi: 10.1074/jbc.M405602200. [DOI] [PubMed] [Google Scholar]
  • [29].Parisiadou L., Efthimiopoulos S. Expression of mDab1 promotes the stability and processing of amyloid precursor protein and this effect is counteracted by X11alpha. Neurobiol Aging. 2007;28:377–388. doi: 10.1016/j.neurobiolaging.2005.12.015. [DOI] [PubMed] [Google Scholar]
  • [30].Lau K.F., McLoughlin D.M., Standen C.L., Irving N.G., Miller C.C. Fe65 and X11β co-localize with and compete for binding to the amyloid precursor protein. Neuroreport. 2000;11:3607–3610. doi: 10.1097/00001756-200011090-00041. [DOI] [PubMed] [Google Scholar]
  • [31].Kwon OY, Hwang, K, Kim, JA, Kim, K, Kwon, IC, Song, HK, et al. Dab1 binds to Fe65 and diminishes the effect of Fe65 or LRP1 on APP processing. J Cell Biochem 2010. [Epub ahead of print]. [DOI] [PubMed]
  • [32].Lee J.H., Barral S., Reitz C. The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer’s disease. Curr Neurol Neurosci Rep. 2008;8:384–391. doi: 10.1007/s11910-008-0060-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33].Small S.A., Gandy S. Sorting through the cell biology of Alzheimer’s disease: intracellular pathways to pathogenesis. Neuron. 2006;52:15–31. doi: 10.1016/j.neuron.2006.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Spoelgen R., von Arnim C.A., Thomas A.V., Peltan I.D., Koker M., Deng A., et al. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and β-secretase β-site APP-cleaving enzyme. J Neurosci. 2006;26:418–428. doi: 10.1523/JNEUROSCI.3882-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35].Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R., Behlke J., et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102:13461–13466. doi: 10.1073/pnas.0503689102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168–177. doi: 10.1038/ng1943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37].Rohe M., Synowitz M., Glass R., Paul S.M., Nykjaer A., Willnow T.E. Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression. J Neurosci. 2009;29:15472–15478. doi: 10.1523/JNEUROSCI.3960-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38].Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709–7717. doi: 10.1523/JNEUROSCI.2177-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].Mackenzie I.R., Miller L.A. Senile plaques in temporal lobe epilepsy. Acta Neuropathol. 1994;87:504–510. doi: 10.1007/BF00294177. [DOI] [PubMed] [Google Scholar]
  • [40].Jankowsky J.L., Xu G., Fromholt D., Gonzales V., Borchelt D.R. Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol. 2003;62:1220–1227. doi: 10.1093/jnen/62.12.1220. [DOI] [PubMed] [Google Scholar]
  • [41].Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., et al. APP processing and synaptic function. Neuron. 2003;37:925–937. doi: 10.1016/S0896-6273(03)00124-7. [DOI] [PubMed] [Google Scholar]
  • [42].Cirrito J.R., Kang J.E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42–51. doi: 10.1016/j.neuron.2008.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [43].Bush A.I. Drug development based on the metals hypothesis of Alzheimer’s disease. J Alzheimers Dis. 2008;15:223–240. doi: 10.3233/jad-2008-15208. [DOI] [PubMed] [Google Scholar]
  • [44].Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7:779–786. doi: 10.1016/S1474-4422(08)70167-4. [DOI] [PubMed] [Google Scholar]
  • [45].Relkin N.R. Testing the mettle of PBT2 for Alzheimer’s disease. Lancet Neurol. 2008;7:762–763. doi: 10.1016/S1474-4422(08)70168-6. [DOI] [PubMed] [Google Scholar]
  • [46].Yu J., Sun M., Chen Z., Lu J., Liu Y., Zhou L., et al. Magnesium modulates amyloid-β protein precursor trafficking and processing. J Alzheimers Dis. 2010;20:1091–1106. doi: 10.3233/JAD-2010-091444. [DOI] [PubMed] [Google Scholar]
  • [47].Sinha S., Anderson J.P., Barbour R., Basi G.S., Caccavello R., Davis D., et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature. 1999;402:537–540. doi: 10.1038/990114. [DOI] [PubMed] [Google Scholar]
  • [48].Hussain I., Powell D., Howlett D.R., Tew D.G., Meek T.D., Chapman C., et al. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol Cell Neurosci. 1999;14:419–427. doi: 10.1006/mcne.1999.0811. [DOI] [PubMed] [Google Scholar]
  • [49].Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., et al. β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735–741. doi: 10.1126/science.286.5440.735. [DOI] [PubMed] [Google Scholar]
  • [50].Yan R., Bienkowski M.J., Shuck M.E., Miao H., Tory M.C., Pauley A.M., et al. Membrane-anchored aspartyl protease with Alzheimer’s disease β-secretase activity. Nature. 1999;402:533–537. doi: 10.1038/990107. [DOI] [PubMed] [Google Scholar]
  • [51].Lin X., Koelsch G., Wu S., Downs D., Dashti A., Tang J. Human aspartic protease memapsin 2 cleaves the β-secretase site of β- amyloid precursor protein. Proc Natl Acad Sci U S A. 2000;97:1456–1460. doi: 10.1073/pnas.97.4.1456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [52].Cai H., Wang Y., McCarthy D., Wen H., Borchelt D.R., Price D.L., et al. BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat Neurosci. 2001;4:233–234. doi: 10.1038/85064. [DOI] [PubMed] [Google Scholar]
  • [53].Yan R., Munzner J.B., Shuck M.E., Bienkowski M.J. BACE2 functions as an alternative β-secretase in cells. J Biol Chem. 2001;276:34019–34027. doi: 10.1074/jbc.M105583200. [DOI] [PubMed] [Google Scholar]
  • [54].Luo Y., Bolon B., Kahn S., Bennett B.D., Babu-Khan S., Denis P., et al. Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci. 2001;4:231–232. doi: 10.1038/85059. [DOI] [PubMed] [Google Scholar]
  • [55].Roberds S.L., Anderson J., Basi G., Bienkowski M.J., Branstetter D.G., Chen K.S., et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum Mol Genet. 2001;10:1317–1324. doi: 10.1093/hmg/10.12.1317. [DOI] [PubMed] [Google Scholar]
  • [56].Fukumoto H., Rosene D.L., Moss M.B., Raju S., Hyman B.T., Irizarry M.C. β-Secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol. 2004;164:719–725. doi: 10.1016/s0002-9440(10)63159-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [57].Yang L.B., Lindholm K., Yan R., Citron M., Xia W., Yang X.L., et al. Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003;9:3–4. doi: 10.1038/nm0103-3. [DOI] [PubMed] [Google Scholar]
  • [58].Cole S.L., Vassar R. The Alzheimer’s disease β-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22. doi: 10.1186/1750-1326-2-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [59].Zhang X., Zhou K., Wang R., Cui J., Lipton S.A., Liao F.F., et al. Hypoxia-inducible factor 1alpha (HIF-1α)-mediated hypoxia increases BACE1 expression and β-amyloid generation. J Biol Chem. 2007;282:10873–10880. doi: 10.1074/jbc.M608856200. [DOI] [PubMed] [Google Scholar]
  • [60].Tamagno E., Guglielmotto M., Aragno M., Borghi R., Autelli R., Giliberto L., et al. Oxidative stress activates a positive feedback between the gamma- and β-secretase cleavages of the β-amyloid precursor protein. J Neurochem. 2008;104:683–695. doi: 10.1111/j.1471-4159.2007.05072.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [61].Shen C., Chen Y., Liu H., Zhang K., Zhang T., Lin A., et al. Hydrogen peroxide promotes Aβ production through JNK-dependent activation of gamma-secretase. J Biol Chem. 2008;283:17721–17730. doi: 10.1074/jbc.M800013200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [62].Cho H.J., Jin S.M., Youn H.D., Huh K., Mook-Jung I. Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling. Aging Cell. 2008;7:137–147. doi: 10.1111/j.1474-9726.2007.00360.x. [DOI] [PubMed] [Google Scholar]
  • [63].Buggia-Prevot V., Sevalle J., Rossner S., Checler F. NFκB-dependent control of BACE1 promoter transactivation by Aβ42. J Biol Chem. 2008;283:10037–10047. doi: 10.1074/jbc.M706579200. [DOI] [PubMed] [Google Scholar]
  • [64].O’Connor T., Sadleir K.R., Maus E., Velliquette R.A., Zhao J., Cole S.L., et al. Phosphorylation of the translation initiation factor eIF2α increases BACE1 levels and promotes amyloidogenesis. Neuron. 2008;60:988–1009. doi: 10.1016/j.neuron.2008.10.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [65].Velliquette R.A., O’Connor T., Vassar R. Energy inhibition elevates β-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer’s disease pathogenesis. J Neurosci. 2005;25:10874–10883. doi: 10.1523/JNEUROSCI.2350-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [66].Guo Q., Fu W., Xie J., Luo H., Sells S.F., Geddes J.W., et al. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat Med. 1998;4:957–962. doi: 10.1038/nm0898-957. [DOI] [PubMed] [Google Scholar]
  • [67].Xie J., Guo Q. PAR-4 is involved in regulation of β-secretase cleavage of the Alzheimer amyloid precursor protein. J Biol Chem. 2005;280:13824–13832. doi: 10.1074/jbc.M411933200. [DOI] [PubMed] [Google Scholar]
  • [68].He W., Lu Y., Qahwash I., Hu X.Y., Chang A., Yan R. Reticulon family members modulate BACE1 activity and amyloid-β peptide generation. Nat Med. 2004;10:959–965. doi: 10.1038/nm1088. [DOI] [PubMed] [Google Scholar]
  • [69].Murayama K.S., Kametani F., Saito S., Kume H., Akiyama H., Araki W. Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid β-protein. Eur J Neurosci. 2006;24:1237–1244. doi: 10.1111/j.1460-9568.2006.05005.x. [DOI] [PubMed] [Google Scholar]
  • [70].Scholefield Z., Yates E.A., Wayne G., Amour A., McDowell W., Turnbull J.E. Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer’s β-secretase. J Cell Biol. 2003;163:97–107. doi: 10.1083/jcb.200303059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [71].He X., Li F., Chang W.P., Tang J. GGA proteins mediate the recycling pathway of memapsin 2 (BACE) J Biol Chem. 2005;280:11696–11703. doi: 10.1074/jbc.M411296200. [DOI] [PubMed] [Google Scholar]
  • [72].Tesco G., Koh Y.H., Kang E.L., Cameron A.N., Das S., Sena-Esteves M., et al. Depletion of GGA3 stabilizes BACE and enhances β-secretase activity. Neuron. 2007;54:721–737. doi: 10.1016/j.neuron.2007.05.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [73].Okada H., Zhang W., Peterhoff C., Hwang J.C., Nixon R.A., Ryu S.H., et al. Proteomic identification of sorting nexin 6 as a negative regulator of BACE1-mediated APP processing. FASEB J. 2010;24(8):2783–2794. doi: 10.1096/fj.09-146357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [74].Teng L., Zhao J., Wang F., Ma L., Pei G. A GPCR/secretase complex regulates β- and γ-secretase specificity for Aβ production and contributes to AD pathogenesis. Cell Res. 2010;20:138–153. doi: 10.1038/cr.2010.3. [DOI] [PubMed] [Google Scholar]
  • [75].Ehehalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160:113–123. doi: 10.1083/jcb.200207113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [76].Sparks D.L., Scheff S.W., Hunsaker J.C., 3rd, Liu H., Landers T., Gross D.R. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88–94. doi: 10.1006/exnr.1994.1044. [DOI] [PubMed] [Google Scholar]
  • [77].Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., et al. Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:5856–5861. doi: 10.1073/pnas.081620098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [78].Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer’s disease. Science. 1989;245:417–420. doi: 10.1126/science.2474201. [DOI] [PubMed] [Google Scholar]
  • [79].Nalivaeva N.N., Fisk L.R., Belyaev N.D., Turner A.J. Amyloid-degrading enzymes as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res. 2008;5:212–224. doi: 10.2174/156720508783954785. [DOI] [PubMed] [Google Scholar]
  • [80].Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J. 2006;6:246–254. doi: 10.1038/sj.tpj.6500369. [DOI] [PubMed] [Google Scholar]
  • [81].Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216–223. doi: 10.1016/S0140-6736(08)61075-2. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES